Categories
- DATA SCIENCE / AI
- AFIR / ERM / RISK
- ASTIN / NON-LIFE
- BANKING / FINANCE
- DIVERSITY & INCLUSION
- EDUCATION
- HEALTH
- IACA / CONSULTING
- LIFE
- PENSIONS
- PROFESSIONALISM
- THOUGHT LEADERSHIP
- MISC
ICA LIVE: Workshop "Diversity of Thought #14
Italian National Actuarial Congress 2023 - Plenary Session with Frank Schiller
Italian National Actuarial Congress 2023 - Parallel Session on "Science in the Knowledge"
Italian National Actuarial Congress 2023 - Parallel Session with Lutz Wilhelmy, Daniela Martini and International Panelists
Italian National Actuarial Congress 2023 - Parallel Session with Kartina Thompson, Paola Scarabotto and International Panelists
4 views
0 comments
0 likes
0 favorites
assa_south-africa
Are GLP-1 weight loss drugs like Ozempic the miracle cure they are made out to be on social media, or are they simply overhyped? In this episode of the ASSA Clarity podcast, host Lucienne Fild sits down with Desigan Pillay, a member of the Actuarial Society of South Africa, to unpack the rapid rise of metabolic health advancements and what they mean for the insurance and actuarial landscapes. Desigan breaks down the three buckets of metabolic health and shares unique insights into South Africa’s distinct obesity demographics. The discussion dives deep into the realities of long-term usage – touching on drug adherence, "yo-yo" usage, muscle and bone mass loss, and the socioeconomic "haves and have-nots" of healthcare access. Finally, they explore the direct operational impacts for life, health, and disability insurers. Tune in for an insightful, data-driven conversation on whether the actuarial profession is ready for the GLP-1 revolution.
0 Comments
There are no comments yet. Add a comment.